---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-072768"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2026-11-10T21:23:34+00:00"
generated_at: "2026-11-10T21:24:06.848603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics Q3 net loss $7.6M; CTIM-76 shows 22% ORR in PROC at weekly doses

## Summary
- Q3 2026 net loss $7.6M vs $9.7M in Q3 2025; R&D $5.7M vs $8.7M, G&A $2.2M vs $1.9M.
- Cash and equivalents $34.4M at Sept 30, 2026, down from $66.0M at Dec 31, 2025; runway expected into early Q4 2027.
- CTIM-76 in 9 efficacy-evaluable PROC patients at 140–280 µg weekly: 22% confirmed ORR, 56% DCR, median PFS 5.6 months.
- Safety: CRS in 5 of 27 patients (18.5%), all Grade 1/2; Grade ≥3 TEAEs in 81.5%, with dose-related Grade ≥3 liver enzyme elevations.
- DLT period at 280 µg every three weeks complete; escalation to 420 µg Q3W begun; Phase 1b initiation expected Q1 2027, initial Q3W efficacy data Q2 2027.

## SEC filing metadata
- accession: 0001628280-26-072768
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2026-11-10T21:23:34+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828026072768/0001628280-26-072768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828026072768/cntx-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-072768
- JSON: https://secwatch.observer/filing/0001628280-26-072768.json
- Plain text: https://secwatch.observer/filing/0001628280-26-072768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.